Breast MRI with a tumoral lession in the left breast, axial view.

Breast MRI with a tumoral lession in the left breast, axial view. Getty Images 


August 30, 2022 — Breast tissue features apparent on MRI are linked with future second breast cancer risk in women with a personal history of breast cancer, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA). 

Breast cancer is the most diagnosed cancer and the leading cause of cancer-related death in women worldwide. While advances in treatment and early detection mean that more women are surviving breast cancer, these women face an increased risk of second breast cancers. 

Breast cancer survivors with dense breasts face an even greater risk of a second cancer. Breast tissue is mostly fatty, with areas of fibrous connective tissue and glandular tissue known collectively as fibroglandular tissue. Women with dense breasts have a greater proportion of fibroglandular tissue and less fatty tissue. This can obscure lesions on mammography and is an independent risk factor for breast cancer. 

Breast MRI has become the preferred method for imaging women with personal history of breast cancer. Previous studies have shown that breast MRI has a higher cancer detection rate than mammography.  

“Postoperative surveillance breast MRI is increasingly being performed according to the American College of Radiology’s annual recommendation for women with dense breasts or those diagnosed with breast cancer before age 50,” said study lead author Su Hyun Lee, M.D., Ph.D., from the Department of Radiology at Seoul National University Hospital in Seoul, Korea. 

Dr. Lee and colleagues studied the link between second cancer risk and background parenchymal enhancement (BPE) at surveillance breast MRI. BPE refers to the brightening, or enhancement, of background tissue on MRI after administration of a contrast agent. The degree of BPE can vary between and within women. It is thought to be related to changes in the blood supply and permeability of breast tissue, which is affected by hormonal status. Breast cancer treatment in the form of radiation therapy, chemotherapy or endocrine therapy can also alter the BPE in the treated breast. 

BPE on contrast-enhanced breast MRI is a known risk factor for breast cancer. Less is known about the links between BPE at surveillance breast MRI and the risk of second breast cancer. 

Of the 2,668 women in the study, 109 developed a second breast cancer at a median follow-up of 5.8 years. Mild, moderate, or marked BPE at surveillance breast MRI was independently associated with an increased risk of future second breast cancer compared to minimal BPE. 

“The results suggest that BPE at postoperative surveillance breast MRI may indicate the response to breast cancer treatment and may be a predictor of the modified risk of second breast cancer after treatment in women with a personal history of breast cancer,” Dr. Lee said. 

The study findings point to a role for BPE measurements in refining screening pathways for women with prior breast cancer, Dr. Lee said. 

“Our study results may help to stratify the risk of second breast cancer in women with a personal history of breast cancer and to establish personalized imaging surveillance strategies in terms of imaging modality and monitoring interval selection,” she said. “For example, women with minimal BPE at surveillance breast MRI may no longer need to undergo contrast-enhanced breast MRI every year if other risk factors are absent.” 

Those other risk factors include younger age at diagnosis, the presence of genetic mutations linked to breast cancer and hormone receptor expression in the initial breast cancer.   

Areas for future study include the link between BPE changes at screening or preoperative breast MRI and at postoperative surveillance breast MRI and the development of second breast cancer. 

In the future, Dr. Lee expects that risk models will use mammography, ultrasound and MRI together. This approach, she said, will lead to more tailored surveillance strategies for women with a history of breast cancer. 

For more information: www.rsna.org 


Related Content

News | Artificial Intelligence

October 6, 2022 — Enlitic, a leading healthcare IT company, announced a new partnership with MULTI Inc., a provider of ...

Time October 06, 2022
arrow
News | Women's Health

October 5, 2022 — Hologic, Inc. Chairman, President and CEO Steve MacMillan rang the Nasdaq opening bell on Monday, Oct ...

Time October 05, 2022
arrow
News | Women's Health

October 4, 2022 — For Black women, breast cancer is the most commonly diagnosed cancer and as of 2019 has surpassed lung ...

Time October 04, 2022
arrow
News | Ultrasound Imaging

October 4, 2022 — During the American College of Emergency Physicians (ACEP) 2022 Scientific Assembly (Oct. 1 – 4, San ...

Time October 04, 2022
arrow
Feature | Radiology Business

Here is a recap of what ITN viewers found most interesting during the month of September: 1. Lasting Lung Damage Seen in ...

Time October 03, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

October 3, 2022 — GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER ...

Time October 03, 2022
arrow
News | Breast Imaging

October 3, 2022 — “Breast cancer doesn’t wait—everything else can.” That’s the message and sense of urgency behind PINK ...

Time October 03, 2022
arrow
Feature | Radiology Imaging

View the September/October digital edition of Imaging Technology News (ITN), including links to videos, comparison ...

Time September 29, 2022
arrow
News | Radiation Oncology

September 28, 2022 — Populations in U.S. counties defined as more vulnerable based on social factors including ...

Time September 28, 2022
arrow
News | Point-of-Care Ultrasound (POCUS)

September 27, 2022 — Fujifilm Sonosite, Inc. – the world leader in point-of-care ultrasound (POCUS) solutions – has ...

Time September 27, 2022
arrow
Subscribe Now